OncoCyte PE Ratio 2014-2023 | OCX
Current and historical p/e ratio for OncoCyte (OCX) from 2014 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. OncoCyte PE ratio as of April 23, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
OncoCyte PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2024-04-23 | 2.46 | 0.00 | |
2023-12-31 | 2.50 | $-1.48 | 0.00 |
2023-09-30 | 3.12 | $-1.48 | 0.00 |
2023-06-30 | 4.60 | $-2.27 | 0.00 |
2023-03-31 | 7.09 | $-2.60 | 0.00 |
2022-12-31 | 6.42 | $-5.20 | 0.00 |
2022-09-30 | 14.60 | $-13.00 | 0.00 |
2022-06-30 | 17.99 | $-14.40 | 0.00 |
2022-03-31 | 29.80 | $-15.40 | 0.00 |
2021-12-31 | 43.40 | $-14.20 | 0.00 |
2021-09-30 | 71.20 | $-8.20 | 0.00 |
2021-06-30 | 114.80 | $-7.20 | 0.00 |
2021-03-31 | 103.80 | $-7.60 | 0.00 |
2020-12-31 | 47.80 | $-9.20 | 0.00 |
2020-09-30 | 27.80 | $-10.40 | 0.00 |
2020-06-30 | 38.20 | $-10.40 | 0.00 |
2020-03-31 | 49.00 | $-9.20 | 0.00 |
2019-12-31 | 45.00 | $-8.80 | 0.00 |
2019-09-30 | 42.00 | $-7.20 | 0.00 |
2019-03-31 | 79.00 | $-7.60 | 0.00 |
2018-12-31 | 27.60 | $-8.40 | 0.00 |
2018-09-30 | 50.00 | $-8.80 | 0.00 |
2018-06-30 | 51.00 | $-9.40 | 0.00 |
2018-03-31 | 42.00 | $-11.40 | 0.00 |
2017-12-31 | 93.00 | $-11.60 | 0.00 |
2019-06-30 | 49.80 | $-12.20 | 0.00 |
2017-09-30 | 151.00 | $-12.40 | 0.00 |
2017-06-30 | 104.00 | $-10.00 | 0.00 |
2017-03-31 | 119.00 | $-9.40 | 0.00 |
2016-12-31 | 141.00 | $-8.60 | 0.00 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Services | $0.021B | $0.002B |
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Elevance Health (ELV) | United States | $123.697B | 15.52 |
Cencora (COR) | United States | $47.247B | 18.86 |
ICON (ICLR) | Ireland | $24.578B | 24.24 |
DiDi Global (DIDIY) | China | $22.930B | 0.00 |
Avantor (AVTR) | United States | $16.557B | 22.81 |
CochLear (CHEOY) | $13.675B | 0.00 | |
Viatris (VTRS) | United States | $13.496B | 3.85 |
Revvity (RVTY) | United States | $12.448B | 21.67 |
EUROFINS SCIENT (ERFSF) | Luxembourg | $12.029B | 0.00 |
Charles River Laboratories (CRL) | United States | $11.979B | 21.84 |
Medpace Holdings (MEDP) | United States | $11.658B | 38.35 |
Solventum (SOLV) | United States | $10.708B | 0.00 |
Natera (NTRA) | United States | $10.700B | 0.00 |
Amplifon S.p.A (AMFPF) | Italy | $7.290B | 37.01 |
HealthEquity (HQY) | United States | $6.966B | 52.04 |
Bausch + Lomb (BLCO) | Canada | $5.145B | 19.78 |
Doximity (DOCS) | United States | $4.625B | 34.43 |
Organon (OGN) | United States | $4.601B | 4.46 |
PACS (PACS) | United States | $3.460B | 0.00 |
Progyny (PGNY) | United States | $3.177B | 53.32 |
Sotera Health (SHC) | United States | $3.139B | 15.40 |
Surgery Partners (SGRY) | United States | $3.044B | 28.28 |
Life Times (LTH) | United States | $2.774B | 30.65 |
GoodRx Holdings (GDRX) | United States | $2.631B | 133.20 |
Premier (PINC) | United States | $2.522B | 9.23 |
Teladoc Health (TDOC) | United States | $2.252B | 0.00 |
AMN Healthcare Services Inc (AMN) | United States | $2.141B | 6.93 |
Agilon Health (AGL) | United States | $2.121B | 0.00 |
BrightSpring Health Services (BTSG) | United States | $1.816B | 0.00 |
Agiliti (AGTI) | United States | $1.368B | 22.33 |
Establishment Labs Holdings (ESTA) | $1.325B | 0.00 | |
NovoCure (NVCR) | Jersey | $1.273B | 0.00 |
Alignment Healthcare (ALHC) | United States | $0.947B | 0.00 |
Pediatrix Medical (MD) | United States | $0.759B | 7.85 |
Embecta (EMBC) | United States | $0.617B | 4.08 |
InnovAge Holding (INNV) | United States | $0.548B | 0.00 |
COMPASS Pathways (CMPS) | United Kingdom | $0.518B | 0.00 |
Enhabit (EHAB) | United States | $0.515B | 46.64 |
Auna S.A (AUNA) | Luxembourg | $0.466B | 0.00 |
CareDx (CDNA) | United States | $0.423B | 0.00 |
LifeMD (LFMD) | United States | $0.404B | 0.00 |
Beauty Health (SKIN) | United States | $0.404B | 0.00 |
Sonida Senior Living (SNDA) | United States | $0.395B | 0.00 |
DocGo (DCGO) | United States | $0.366B | 58.50 |
MultiPlan (MPLN) | United States | $0.356B | 0.00 |
Sera Prognostics (SERA) | United States | $0.317B | 0.00 |
ModivCare (MODV) | United States | $0.312B | 4.14 |
GeneDx Holdings (WGS) | United States | $0.271B | 0.00 |
Ascend Wellness Holdings (AAWH) | United States | $0.260B | 0.00 |
Sharecare (SHCR) | United States | $0.250B | 0.00 |
So-Young (SY) | China | $0.131B | 44.00 |
Biodesix (BDSX) | United States | $0.125B | 0.00 |
Oncology Institute (TOI) | United States | $0.084B | 0.00 |
Pono Capital Two (PTWO) | United States | $0.063B | 0.00 |
IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
NeueHealth (NEUE) | United States | $0.052B | 0.00 |
Co-Diagnostics (CODX) | United States | $0.036B | 0.00 |
Nutex Health (NUTX) | United States | $0.034B | 0.00 |
Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
SeaStar Medical Holding (ICU) | United States | $0.024B | 0.00 |
DermTech (DMTK) | United States | $0.021B | 0.00 |
BIMI Holdings (BIMI) | United States | $0.013B | 0.00 |
Aesthetic Medical Hldngs Group (AIH) | China | $0.012B | 0.00 |
BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
OpGen (OPGN) | United States | $0.008B | 0.00 |
XWELL (XWEL) | United States | $0.006B | 0.00 |
NewGenIvf Group (NIVF) | Singapore | $0.005B | 0.00 |
Assure Holdings (IONM) | United States | $0.004B | 0.00 |
ISpecimen (ISPC) | United States | $0.003B | 0.00 |
Aclarion (ACON) | United States | $0.002B | 0.00 |